Read more
4:36 PM · 27 April 2021

Eli Lilly results disappointed investors

-
-
Open account Download free app

Eli Lilly (LLY.US) stock fell nearly 4% after the drugmaker posted disappointing quarterly figures. Company earned $1.87 per share which came well below analysts’ expectations of $2.14 a share. Lilly reported revenue of $6.81 billion in the first quarter, short of the average market estimate of $7.02 billion. Company recorded a 7% fall in quarterly profit, due to higher spending on research and development of treatments including Covid-19 drugs. Also Lilly took various asset impairment charges during the quarter, as well as incurring costs related to its acquisition of Prevail Therapeutics. The company also lowered its full-year earnings forecast due to lower demand for its COVID-19 antibody therapies with the U.S. vaccine rollout in full swing. Drugmaker now expects adjusted full-year earnings of $7.80 to $8.00 per share, from its prior forecast of $7.75 to $8.40 per share.

Eli Lilly (LLY.US) stock launched today’s session with a bearish price gap and is currently testing lower limit of the ascending channel. Should break lower occur, then downward move may be extended to the support at 173.83. On the other hand, if buyers will manage to halt declines here, then another upward move towards major resistance at $197.28 is possible. Source: xStation5

17 February 2026, 2:58 PM

US OPEN: Market under pressure from AI

17 February 2026, 2:52 PM

Hollywood on Edge: Another Round in the Battle for Warner Bros.

17 February 2026, 1:24 PM

Norwegian Cruise Line surges 7% amid disclosed Elliott Management 10% stake 📈

17 February 2026, 12:35 PM

BHP Results, the Copper Market, and the KGHM Correction. What You Need to Know

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits